Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. HOOD
8. DFTX
9. USO
10. MSFT

Go back to Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results

November 12, 2015 7:01 AM EST

COPENHAGEN, Denmark, Nov. 12, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and nine months ended September 30, 2015.

Ascendis Pharma reported a cash balance of 128.2 million at September 30, 2015.

"Our recent Phase 2 pediatric study presentation at the 54th Annual Meeting of the European Society of Pediatric Endocrinology confirmed once-weekly TransCon Growth Hormone's attractive profile to a large, international clinically-focused audience," stated Jan Mikkelsen, President and Chief Executive Officer of... More

Ascendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference

November 11, 2015 4:05 PM EST

COPENHAGEN, Denmark, Nov. 11, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at an upcoming investor conference.

Event:... More